SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2
作者机构:CAS Key Laboratory of Receptor ResearchDrug Discovery and Design CenterShanghai Institute of Materia MedicaChinese Academy of SciencesShanghai 201203China College of Computer Science and TechnologyNational University of Defense TechnologyChangsha 410073China Center for Drug Safety Evaluation and ResearchShanghai Institute of Materia MedicaChinese Academy of SciencesShanghai 201203China
出 版 物:《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗(英文))
年 卷 期:2022年第7卷第2期
页 面:359-361页
核心收录:
学科分类:0710[理学-生物学] 1007[医学-药学(可授医学、理学学位)] 100705[医学-微生物与生化药学] 1001[医学-基础医学(可授医学、理学学位)] 100103[医学-病原生物学] 10[医学]
基 金:This work was supported by the Natural Science Foundation of Shanghai(21ZR1475600) National Key R&D Program of China(2016YFA0502301&2017YFB0202601) the National Science Foundation of China(U1811462) the open fund from the State Key Laboratory of High-Performance Computing(No.201901-11) The work was partially carried out on the new generation Tianhe Supercomputer
摘 要:Dear Editor,SARS-coronavirus-2(SARS-CoV-2)Omicron variant(B.1.1.529)is of great concern to the world due to its multiple mutations that may have an impact on transmissibility and immune evasion.1 Compared to the wild type(WT),Omicron carries as many as 30 single point mutations,3 deletion mutation and one insertion mutation on its spike ***,there are 15 mutations observed in the Omicron receptor-binding domain(RBD),10 of which are in the receptor-binding motif(RBM)that human angiotensin-converting enzyme 2(ACE2)and most monoclonal antibodies(mAbs)interact directly *** a comparison,the currently dominant variant Delta(B.1.617.2)has only 2 mutations(L452R and T478K)in its RBM and additional K417N and E484K mutations ***,Omicron variant may significantly impact the binding affinity to ACE2 and effectiveness of currently available ***,Omicron mutant has aroused wide concern,many countries have taken measures on entry restrictions to prevent its rapid ***,the transmissibility and immune evasion risk of Omicron have not been properly evaluated.